Patents Assigned to Genentech
  • METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HERPESVIRUSES
    Publication number: 20240011017
    Abstract: Provided herein are methods of treating or preventing herpesvirus infection comprising modulating interactions between herpesvirus surface proteins and plasma membrane-expressed host cell proteins, as well as methods of identifying modulators of such interactions.
    Type: Application
    Filed: August 21, 2023
    Publication date: January 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Nadia MARTINEZ-MARTIN, Bushra HUSAIN
  • PRODUCTION CELLS
    Publication number: 20240011066
    Abstract: Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.
    Type: Application
    Filed: April 19, 2023
    Publication date: January 11, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Shahram Misaghi, Amy Shen, Inn Huam Yuk, Gavin Christian Barnard, Simon Auslaender, Niels Bauer, Benedikt Oswald
  • Bispecific antigen-binding molecules and methods of use
    Patent number: 11866498
    Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Diego Ellerman, Teemu T. Junttila, Twyla Noelle Lombana, Dionysos Slaga, Christoph Spiess
  • Humanized anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 11866496
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Composition and methods for stabilizing liquid protein formulations
    Patent number: 11865177
    Abstract: The present disclosure provides liquid formulations comprising polypeptides and surfactants. In particular, it discloses a liquid formulation comprising a polypeptide and a surfactant, wherein at least about 70% (wt %) of the surfactant are isosorbide polyoxyethylene (POE) fatty acid esters. The invention also provides methods for making such liquid formulations, articles of manufacture comprising such liquid formulations and methods of treating a patient with such liquid formulations.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 9, 2024
    Assignee: GENENTECH, INC.
    Inventors: Anthony Tomlinson, Barthelemy Luc Demeule, Isidro Angelo Eleazar Zarraga
  • INDUCTIVE HEAT STERILIZING SYSTEMS, DEVICES, AND METHODS
    Publication number: 20240000985
    Abstract: A system for making a sterile connection of at least one conduit is provided. The system includes a clamp for securing the conduit and for delivering inductive energy to sterilize an interior of the conduit. The system includes an insert for delivering inductive energy to sterilize an interior of the conduit. The system includes a cradle for directly supporting the clamp and indirectly supporting the insert inside the conduit. The system includes an operating system and a device for generating inductive heat. Related methods, apparatuses, devices, systems, techniques and articles are also described.
    Type: Application
    Filed: May 31, 2023
    Publication date: January 4, 2024
    Applicant: Genentech, Inc.
    Inventors: Luis Fernando Caldera, Arthi Narayanan, Trishna Ray-Chaudhuri, Nicholas Rummel
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20240000776
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: September 7, 2023
    Publication date: January 4, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Diagnostic and therapeutic methods for cancer
    Patent number: 11859252
    Abstract: The present invention provides diagnostic and therapeutic methods and compositions for cancer. The invention provides methods of determining whether an individual having a cancer is likely to respond to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of predicting responsiveness of an individual having a cancer to treatment comprising a pan-RAF dimer inhibitor and a MEK or PI3K inhibitor, methods of selecting a therapy for an individual having a cancer, and methods of treating an individual having cancer based on the presence of a biomarker of the invention (e.g., a KRAS activating mutation, e.g., a KRAS-G13D mutation, or an NRAS activating mutation).
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: January 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Christiaan Nicolaas Klijn, Shiva Malek, Ivana Yen
  • Bioanalytical analysis of site-specific antibody drug conjugates
    Patent number: 11860156
    Abstract: Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: January 2, 2024
    Assignee: Genentech, Inc.
    Inventors: Martine Darwish, Surinder Kaur, Dian Su, Keyang Xu
  • COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF
    Publication number: 20230416401
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Application
    Filed: February 9, 2023
    Publication date: December 28, 2023
    Applicant: Genentech, Inc.
    Inventors: Reed J. HARRIS, Paul MOTCHNIK
  • USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASE
    Publication number: 20230416825
    Abstract: Provided herein are methods of treating a subject, methods of predicting the response of a subject and selecting a subject suffering from a disease associated with KLK5, such as asthma or Netherton Syndrome. In particular, provided herein are uses of KLK5 antagonists for the treatment or diagnosis of asthma or Netherton Sydrome, such as an antibody or an Fc fusion polypeptide as well as pharmaceutical formulations comprising the same.
    Type: Application
    Filed: March 29, 2023
    Publication date: December 28, 2023
    Applicant: Genentech, Inc.
    Inventors: Amy Dressen, David B. Iaea, Moulay Hicham Alaoui Ismaili, Janet K. Jackman, Robert A. Lazarus, Kelly Michele Loyet, Henry R. Maun, Brian Louis Yaspan, Tangsheng Yi, Joseph R. Arron, Hilda Y Hernandez-Barry
  • TREATMENT OF OPHTHALMOLOGIC DISEASES
    Publication number: 20230416353
    Abstract: The current invention relates to the use of antibodies which bind to VEGF and ANG2 for the treatment of ophthalmologic diseases.
    Type: Application
    Filed: February 9, 2023
    Publication date: December 28, 2023
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: Aaron Osborne, Jayashree Sahni, Robert James Weikert
  • Polypeptide expression systems
    Patent number: 11851661
    Abstract: The present invention relates to polypeptide expression systems and methods of using the same.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: December 26, 2023
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Yonglei Shang
  • Multispecific antibodies
    Patent number: 11851501
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: December 26, 2023
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Jenny M. Bostrom
  • FLUORESCENT ELLMAN ASSAY FOR FREE THIOL DETECTION
    Publication number: 20230408416
    Abstract: The present disclosure relates to methods and kits for detecting a free thiol in a substrate as well as methods for quantifying the amount of free thiol in a substrate. In particular, the present disclosure provides a fluorescent Ellman assay for enhanced sensitivity of free thiol detection and quantification.
    Type: Application
    Filed: April 28, 2023
    Publication date: December 21, 2023
    Applicant: GENENTECH, INC.
    Inventors: Aron Lee, Rashmi Sharma, Justin Joo-Ho Jeong, Michael Tae-Jon Kim
  • Apparatus and methods for low-volume medicament delivery
    Patent number: 11844938
    Abstract: Apparatus and methods for delivering medicament. The apparatus may include a fitting for a fluid dispenser. The fitting may include a detent that is configured to limit insertion of the dispenser into the fitting by contacting a terminal surface of the dispenser; and a seal for sealing against the surface. The apparatus may include an insert for the fitting. The insert may include a gasket to seal against the terminal surface of the dispenser; a proximal rim to engage a lateral wall of the dispenser; and a connector fixed to the gasket and the rim. The apparatus may include a coupler to engage a pre-filled dispenser; and a body defining a passageway that is configured to be placed in fluid communication with the dispenser. The apparatus may include a dispenser that includes a detent and a seal. The detent may limit insertion of the dispenser into a fitting.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: December 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Lionel Vedrine, Ariel Waitz
  • Anti-Ly6G6D antibodies and methods of use
    Patent number: 11845799
    Abstract: Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: December 19, 2023
    Assignee: Genentech, Inc.
    Inventors: WeiYu Lin, Christoph Spiess, Liping Sun, Yan Wu, Cecilia P. C. Chiu, Walter Christian Darbonne, Michael Andrew Dillon
  • COMPLEMENT COMPONENT C1S INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME
    Publication number: 20230399643
    Abstract: The present invention relates to complement component 1s (C1S) inhibitors for use in treatment of neurological diseases. The invention in particular relates to the use of C1S inhibitors for down-regulation of C1S expression. The invention also relates to nucleic acid molecules, which are complementary to C1S and capable of reducing the level of an C1S mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of neurological diseases.
    Type: Application
    Filed: November 9, 2022
    Publication date: December 14, 2023
    Applicant: Genentech, Inc.
    Inventors: Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
  • 1-(2-(4-CYCLOPROPYL-1H-1,2,3-TRIAZOL-1-YL)ACETYL)-4-HYDROXY-N-(BENZYL)PYRROLIDIN E-2-CARBOXAMIDE DERIVATIVES AS VHL INHIBITORS FOR THE TREATMENT OF ANEMIA AND CANCER
    Publication number: 20230391766
    Abstract: The present disclosure relates to compounds comprising a VHL ligand moiety and to methods of using such compounds as ligands of VHL. The present disclosure further relates to the use of the compounds described herein, or pharmaceutical compositions thereof, to prevent and/or treat a range of diseases, disorders, and conditions.
    Type: Application
    Filed: May 9, 2023
    Publication date: December 7, 2023
    Applicant: Genentech, Inc.
    Inventors: Jakob FUHRMANN, Hao WU, Wayne J. FAIRBROTHER
  • Display screen or portion thereof with graphical user interface
    Patent number: D1009935
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: January 2, 2024
    Assignee: GENENTECH, INC.
    Inventor: Philip Thepkaysone